Stakeholders Urge Congress to Advance Antibiotic Development

COVID-19 response legislation should include economic incentives, funds for stewardship in hospitals

Stakeholders Urge Congress to Advance Antibiotic Development

The Pew Charitable Trusts, the Infectious Diseases Society of America, and dozens of other nonprofit and industry stakeholder groups sent a letter to Congress on May 8 encouraging lawmakers to enact a package of economic incentives in its next COVID-19 emergency relief package to stabilize the failing antibiotic market and address the challenges that hinder antibiotic development.

The organizations note that any such incentives must be paired with efforts to ensure that these drugs are used appropriately, including provision of federal funding to help hospitals establish antibiotic stewardship programs and report use and resistance data to the Centers for Disease Control and Prevention.

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.